Click Here for Additional Resources
A conversation with Michaeline Daboul, CEO of MMIS, about her company's third annual survey of doctors and their knowledge of the Sunshine Law, which is part of Obamacare. The survey found that physicians are actually less informed than they were one year ago. Also participating in the discussion is Tim Robinson, Esq., Executive Vice President & General Counsel at MMIS. See Bios.
Aired LIVE on: Wednesday, March 13, 2013
Find Additional Business Podcasts with Pharmaguy
MMIS' third annual survey of doctors and their knowledge of the Sunshine Act found that physicians are actually less informed than they were one year ago. With the release of the final rules implementing the Sunshine Law on February 1, 2013, consumers and interested parties will have access to a comprehensive and searchable database to review certain payments and transfers of value made by pharmaceutical and medical device manufactures to physicians and teaching hospitals. The Sunshine Act is intended to increase transparency on the relationships between physicians and pharmaceutical and medical device companies.
The survey revealed that of the more than 1,000 physicians questioned, over half admitted they didn't know that the law requires pharmaceutical and medical device companies to report on expenditures annually, without physician review of the data to correct any inconsistencies or errors, prior to submission to the government. 63% were deeply concerned that a record of these payments will be available in a publicly searchable database.
- Background regarding the sunshine law, including important dates for implementation.
- Survey methodology
- A summary of survey results and what they tell us -- pharma companies might be surprised!
- How can physicians review the data before it goes public to correct inaccuracies.
- What is at stake for pharma companies if they do not work more closely with physicians regarding access to the data?
- What the industry must do to educate their physician clients about the Sunshine Law
- Will this new form of "Big Data" eventually lead to a significant decrease in payments of all kinds to physicians by the drug industry?
Michaeline Daboul is a veteran of the medical technology and pharmaceutical industries, with over 25 years of experience working in genomics research, pharmaceutical drug development and marketing, and medical systems innovation. She has led organizations in the development of new technologies to create products and services for their Fortune 500 clients. She has spent the past 13 years as the founding president of MMIS, leading the company in the development of enterprise platforms and software solutions for clients around the world. Most recently, she has spearheaded the creation of groundbreaking collaboration platforms that provide secure interactions between physicians, clinical researchers, and life science companies.
Ms. Daboul is a graduate of Rutgers University, where she received a B.S. in Biochemistry.
Tim Robinson started his law career in private practice, assisting entrepreneurial organizations with corporate formation, fund raising, and intellectual property law. Throughout the last 10 years, he has served as General Counsel for MMIS and has worked with numerous Fortune 500 companies to develop innovative products and services in the highly regulated healthcare and pharmaceutical industries. Recently, Mr. Robinson has been involved in the development and implementation of secure networks to facilitate collaboration among University researchers/scientists and industry professionals.
Mr. Robinson is a graduate of the Boston University School of Law, where he received an LLM.